PuraPharm (HKSE:01498) Total Liabilities : HK$651.3 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Total Liabilities?

PuraPharm's Total Liabilities for the quarter that ended in Jun. 2024 was HK$651.3 Mil.

PuraPharm's quarterly Total Liabilities declined from Jun. 2023 (HK$730.05 Mil) to Dec. 2023 (HK$690.73 Mil) and declined from Dec. 2023 (HK$690.73 Mil) to Jun. 2024 (HK$651.26 Mil).

PuraPharm's annual Total Liabilities declined from Dec. 2021 (HK$804.31 Mil) to Dec. 2022 (HK$758.21 Mil) and declined from Dec. 2022 (HK$758.21 Mil) to Dec. 2023 (HK$690.73 Mil).

PuraPharm Total Liabilities Historical Data

The historical data trend for PuraPharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Total Liabilities Chart

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

860.12

862.92

804.31

758.21

690.73

PuraPharm Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															727.75	758.21	730.05	690.73	651.26

PuraPharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PuraPharm's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	571.089	+	(102.775	+	2.8189999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	14.044)
	=	690.7

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	843.963	-	153.236
	=	690.7

PuraPharm's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	510.222	+	(123.644	+	2.583
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	14.044)
	=	651.3

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	781.732	-	130.471
	=	651.3

PuraPharm Total Liabilities Related Terms

Thank you for viewing the detailed overview of PuraPharm's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.

Executives

Chan Yu Ling, Abraham	2101 Beneficial owner
Man Yee Wai, Viola	2202 Interest of your spouse
Fullgold Development Limited	2101 Beneficial owner

PuraPharm Headlines

No Headlines